PhorMed
Utilizing gene therapy to target cancer and mutated cells
Analytics
Raised: $196,051
Aggregate Commitments $
StartEngine
05/24/2022
08/17/2022
$10,000
$2,150,494
$500
Equity - Common
RegCF
Seed
$1.00
$51,647,023
Rolling Commitments $
Active
06/25/2022
53
1,961%
9%
$6,127
Beverly Hills, California
Healthcare & Pharmaceuticals
Biotech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-573,854 |
$-948,160 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$105,694 |
$109,844 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$183,724 |
$340,922 |
Short-Term Debt |
$227,264 |
$363,294 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$227,264 |
$363,294 |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual